Day: August 14, 2025

ENGLEWOOD CLIFFS, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) — Atlantic International Corp. (Nasdaq: ATLN), a leading strategic staffing, outsourced services, and workforce solutions company, today announced financial results for the second quarter ended June 30, 2025, demonstrating significant operational improvements and a strengthened financial position. Second Quarter 2025 Highlights:Net loss narrowed by 81% to $10.7 million (or $0.20 per share), compared to a net loss of $54.9 million (or $1.96 per share) in Q2 2024 Service revenue was $102.9 million, with permanent placement services up 17% year-over-year. Gross profit margin improved to 11.1%, reflecting pricing discipline and efficiency. Operating cash flow was $5.0 million for the six months, improving from $(4.2) million a year ago. Enhanced financial flexibility by securing...

Initial data from the 50 mg dose in the open label study and the adolescent PK run-in study planned for program update in September 2025 Adolescent participants from the PK run-in study and patients with FA who have not participated in prior nomlabofusp clinical studies are currently screening and enrolling in the open label study; planning to enroll children (2 to 11 years of age) directly into the open label study FDA recommended that the safety database include at least 30 participants with continuous study drug exposure for 6 months, and a subset of at least 10 participants for 1-year; large majority of safety data should be from participants receiving 50 mg nomlabofusp Published two peer-reviewed articles; the nonclinical data included in the publications were part of the data submitted to FDA to support the mechanism of action of...

Strong Bookings and continuing SaaS Revenue growth Q2 2025 Highlights 1  Revenue (in $ millions)  SaaS Subscription Recurring TotalReported Y/Y growth Reported Y/Y growth Reported Y/Y growth$7.9 13.1% $10.9 4.0% $15.7 (6.9)% SaaS ARR up 12.5% Y/Y to $31.7 million; Total ARR up 3% Y/Y to $43.8 million; SaaS NRR of 107%; Bookings up 33% Y/Y to 17.1 million; Adjusted EBITDA margin of 15.3% or $2.4 million; Gross profit margin of 58%; and Recurring Revenue at 70% of Total Revenue.CALGARY, Alberta, Aug. 14, 2025 (GLOBE NEWSWIRE) — Sylogist Ltd. (TSX: SYZ) (“Sylogist” or the “Company”), a leading public sector SaaS company, today announced its results for the second quarter of fiscal 2025, ended June 30, 2025. “I am very pleased with our Q2 performance,” said Bill Wood, CEO of Sylogist. “In...

– WTX-124 Phase 1/1b clinical trial on track for interim data readout in the fourth quarter of 2025, including patients in both the monotherapy and combination expansion arms of cutaneous melanoma and renal cell carcinoma – – Planning to engage with U.S. Food & Drug Administration (FDA) in the second half of 2025 to discuss potential registrational pathways for WTX-124 in advanced or metastatic cutaneous melanoma – – Phase 1b/2 clinical trial of WTX-330 is actively enrolling, with anticipated determination of dosing regimen by the end of 2025 – – Company announces WTX-1011, its first INDUCER™ T-cell engager development candidate, targeting STEAP1 – WATERTOWN, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering...

PRT7732, once daily oral SMARCA2 degrader, currently enrolling at the seventh dosing cohort (125 mg); Company to provide an update with preliminary clinical data, including PK/PD, safety and initial clinical activity by year end 2025 Phase 1 study of PRT3789, a once weekly IV SMARCA2 degrader, has been completed; Company to provide final data by year end 2025 Prelude is advancing a development candidate for its oral KAT6A degrader program and remains on track to file an IND in the first half of 2026 Current cash runway into the second quarter of 2026 with $77.3 million in cash, cash equivalents, restricted cash and marketable securities as of June 30, 2025  WILMINGTON, Del., Aug. 14, 2025 (GLOBE NEWSWIRE) — Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported its financial...

Record Quarterly Revenue of $2.77 million Post-Quarter ETH Holdings Surpass $321 Million SILVER SPRING, Md., Aug. 14, 2025 (GLOBE NEWSWIRE) — BTCS Inc. (Nasdaq: BTCS) (“BTCS” or the “Company”), a blockchain technology-focused company, short for Blockchain Technology Consensus Solutions, today announced its financial results for the three and six months ended June 30, 2025 (“Q2 2025”). Further, the Company updated its investor presentation, which can be found on its refreshed website at www.btcs.com. “BTCS delivered record quarterly and year-to-date revenues in Q2 2025, surpassing our prior annual revenue record in the first six months of 2025,” said Charles Allen, CEO of BTCS. “Builder+ operations focused on Ethereum drove a 394% year-over-year revenue increase. These achievements are a testament to our successful execution of...

Thomas E. Hogan Named CEO ARR grew 21% to $418.9 million; Revenue grew 18% to $113.3 million Net income of $19.5 million supports non-GAAP net income of $30.8 million and adjusted EBITDA of $27.9 million, 24.6% adjusted EBITDA margin TYSONS CORNER, Va. and PETAH TIKVA, Israel, Aug. 14, 2025 (GLOBE NEWSWIRE) — Cellebrite (NASDAQ: CLBT), a global leader in premier Digital Investigative solutions for the public and private sectors, today announced financial results for the three and six months ending June 30, 2025 and the appointment of Thomas E. Hogan as the Company’s CEO. “Cellebrite delivered a strong balance of top-line growth, profitability and cash flow,” stated Thomas E. Hogan, Cellebrite’s CEO. “The Company converted 18% revenue growth into a 29% increase in adjusted EBITDA while free cash flow grew 133% to $29.0 million,...

– Type A Meeting requested with U.S. Food and Drug Administration (FDA) for resolution of the Complete Response Letter (CRL) for oxylanthanum carbonate (OLC) – OLC pivotal study data, published in the Clinical Journal of the American Society of Nephrology (CJASN), demonstrated OLC was well tolerated and enabled serum phosphate control in over 90% of patients with a low pill burden – Ended Q2 with $22.3 million of cash with expected runway into the second half of 2026 LOS ALTOS, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the three months ended June 30, 2025, and provided a business update. “Our team has...

OMAHA, NE, Aug. 14, 2025 (GLOBE NEWSWIRE) — FitLife Brands, Inc. (“FitLife” or the “Company”) (NASDAQ: FTLF), a provider of innovative and proprietary nutritional supplements and wellness products, today announced financial results for the second quarter ended June 30, 2025. Highlights for the second quarter ended June 30, 2025 include:Total revenue was $16.1 million, 5% lower than the second quarter of 2024.   Online revenue was $10.4 million, representing 65% of total revenue and down 7% compared to the second quarter of 2024. Gross margin was 42.8% compared to 44.8% during the second quarter of 2024. Net income for the second quarter of 2025 was $1.7 million compared to $2.6 million during the same period last year, with merger and acquisition related expense associated with the Irwin Naturals transaction accounting for most...

Planned strategic combination with Beckley Psytech expected to solidify position as global leader in transformative, psychedelic-based mental health therapies with a short time in-clinicReported positive topline data from the core, blinded stage of the Phase 2b clinical trial of BPL-003 (intranasal mebufotenin benzoate) in patients with treatment-resistant depression (TRD) BPL-003 met its primary and all key secondary endpoints, and demonstrated rapid, robust and durable antidepressant effects for up to 8 weeks with a single dose Topline data from the eight-week open-label extension stage of the Phase 2b clinical trial of BPL-003 is expected in the third quarter of 2025 On track to submit End-of-Phase 2 meeting request to the U.S. Food and Drug Administration (FDA) in the third quarter of 2025 Cash, cash equivalents, short-term securities,...